Literature DB >> 20069794

Solubility and stability enhancement of atorvastatin by cyclodextrin complexation.

Chinna Reddy Palem1, Shweta Patel, Varsha B Pokharkar.   

Abstract

The objective of the study was to increase the solubility, stability, and dissolution rate of atorvastatin calcium (ATN Ca), a poorly water-soluble 3-hydroxy 3-methyl glutaryl CoA (HMG-CoA) reductase inhibitor through inclusion complexation with beta-cyclodextrin (beta-CD). The phase solubility profile indicated that the solubility of ATN Ca was significantly increased in the presence of beta-CD and was classified as AL-type, indicating the 1:1 stoichiometric inclusion complexes. Solid complexes prepared by physical mixing, kneading, co-evaporation, and freeze-drying methods were characterized using differential scanning calorimetry, fourier transform infrared spectroscopy, and powder X-ray diffractometry. In vitro studies showed that the solubility and dissolution rate of ATN Ca were significantly improved by complexation with beta-CD with respect to the drug alone. In contrast, freeze-dried product showed higher solubility and dissolution rates than the other complexes. ATN Ca unit dosage form was developed and evaluated for physico-chemical properties, stability, and dissolution rate. The stability of tablets was studied and no significant changes were detected in the dissolution profile of tablets after 1 month.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20069794

Source DB:  PubMed          Journal:  PDA J Pharm Sci Technol        ISSN: 1079-7440


  11 in total

1.  Computationally designed prodrugs of statins based on Kirby's enzyme model.

Authors:  Rafik Karaman; Wajd Amly; Laura Scrano; Gennaro Mecca; Sabino A Bufo
Journal:  J Mol Model       Date:  2013-07-09       Impact factor: 1.810

2.  Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation.

Authors:  Furquan Nazimuddin Khan; Mohamed Hassan G Dehghan
Journal:  AAPS PharmSciTech       Date:  2011-08-31       Impact factor: 3.246

3.  Development and validation of a discriminative dissolution method for atorvastatin calcium tablets using in vivo data by LC and UV methods.

Authors:  J C Machado; A D Lange; V Todeschini; N M Volpato
Journal:  AAPS PharmSciTech       Date:  2013-11-22       Impact factor: 3.246

4.  Enhanced Bioavailability and Dissolution of Atorvastatin Calcium from Floating Microcapsules using Minimum Additives.

Authors:  Furquan Nazimuddin Khan; Mohamed Hassan G Dehghan
Journal:  Sci Pharm       Date:  2011-11-05

5.  Formulation of Gelucire®-Based Solid Dispersions of Atorvastatin Calcium: In Vitro Dissolution and In Vivo Bioavailability Study.

Authors:  Basmah N Aldosari; Alanood S Almurshedi; Iman M Alfagih; Bushra T AlQuadeib; Mohammad A Altamimi; Syed Sarim Imam; Afzal Hussain; Faleh Alqahtani; Ehab Elzayat; Sultan Alshehri
Journal:  AAPS PharmSciTech       Date:  2021-05-24       Impact factor: 4.026

6.  Development and optimization of a self-microemulsifying drug delivery system for atorvastatin calcium by using D-optimal mixture design.

Authors:  Dong Woo Yeom; Ye Seul Song; Sung Rae Kim; Sang Gon Lee; Min Hyung Kang; Sangkil Lee; Young Wook Choi
Journal:  Int J Nanomedicine       Date:  2015-06-05

7.  Dissolution Improvement of Atorvastatin Calcium using Modified Locust Bean Gum by the Solid Dispersion Technique.

Authors:  Dharmila Panghal; Manju Nagpal; Gurjeet Singh Thakur; Sandeep Arora
Journal:  Sci Pharm       Date:  2013-12-09

8.  Novel sublingual tablets of Atorvastatin calcium/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization.

Authors:  Noha N Atia; Hesham M Tawfeek; Azza H Rageh; Marwa R El-Zahry; Ahmed Abdelfattah; Mahmoud A Younis
Journal:  Saudi Pharm J       Date:  2019-02-05       Impact factor: 4.330

9.  Dissolution Enhancement of Atorvastatin Calcium by Cocrystallization.

Authors:  Reham Al-Kazemi; Yacoub Al-Basarah; Aly Nada
Journal:  Adv Pharm Bull       Date:  2019-10-24

10.  Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release.

Authors:  Sanjay Dey; Sankha Chattopadhyay; Bhaskar Mazumder
Journal:  Biomed Res Int       Date:  2014-01-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.